<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04953611</url>
  </required_header>
  <id_info>
    <org_study_id>2013116</org_study_id>
    <nct_id>NCT04953611</nct_id>
  </id_info>
  <brief_title>Quantitative Study on HRCT Phenotype of COPD</brief_title>
  <official_title>Quantitative Study on HRCT Phenotype of the GOLD COPD Assessment Staging</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University Third Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University Third Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To explore the HRCT phenotype of the combined COPD assessment staging system&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      HRCT can be rapidly and safely deployed has enabled COPD research to move beyond FEV1 by&#xD;
      facilitating and amplifying clinical phenotyping measurements, providing quantitative&#xD;
      information, and detecting significant responses to therapy even in the absence of&#xD;
      significant FEV1 improvements.&#xD;
&#xD;
      We explore the HRCT phenotype of the combined COPD assessment staging system,and found that:&#xD;
&#xD;
        1. Airway remodeling occurs in COPD patients. CT shows varying degrees of bronchial wall&#xD;
           thickness, area increasing and emphysema as the new GOLD classification Group A-D&#xD;
           arising.&#xD;
&#xD;
        2. The GOLD Combined assessment staging system helps doctors choose an individualized&#xD;
           treatment for the COPD patients&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 1, 2013</start_date>
  <completion_date type="Actual">November 30, 2014</completion_date>
  <primary_completion_date type="Actual">November 30, 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The severity of emphysema</measure>
    <time_frame>Within an average of 3 days after diagnosis of COPD</time_frame>
    <description>% low attenuation area &lt;950 HU (LAA %)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Indicator A of the severity of airway stenosis</measure>
    <time_frame>Within an average of 3 days after diagnosis of COPD</time_frame>
    <description>The inner diameter of bronchial (LD) in centimeter</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Indicator B of the severity of airway stenosis</measure>
    <time_frame>Within an average of 3 days after diagnosis of COPD</time_frame>
    <description>The bronchial wall thickness in centimeter</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Indicator C of the severity of airway stenosis</measure>
    <time_frame>Within an average of 3 days after diagnosis of COPD</time_frame>
    <description>Ratio of thickness and outer diameter (TDR)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Indicator D of the severity of airway stenosis</measure>
    <time_frame>Within an average of 3 days after diagnosis of COPD</time_frame>
    <description>% wall area for bronchial external diameter (WA%)</description>
  </primary_outcome>
  <number_of_groups>5</number_of_groups>
  <enrollment type="Actual">150</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>Group A in GOLD</arm_group_label>
    <description>CAT&lt;10、mMRC 0-1、FEV1%≥50%、the frequency of acute exacerbations in the past year&lt;2；</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B in GOLD</arm_group_label>
    <description>CAT≥10、mMRC≥2、FEV1%≥50%、the frequency of acute exacerbations in the past year&lt;2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C in GOLD</arm_group_label>
    <description>CAT&lt;10、mMRC 0-1、 FEV1%&lt;50%、the frequency of acute exacerbations in the past year≥2 or leading to hospital admission≥1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group D in GOLD</arm_group_label>
    <description>CAT≥10、mMRC≥2、FEV1%&lt;50%、the frequency of acute exacerbations in the past year≥2 or leading to hospital admission≥1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <description>not COPD</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        consecutive outpatients&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age between 40 and 80 (including 40 and 80)&#xD;
&#xD;
          2. It meets the diagnostic criteria for COPD&#xD;
&#xD;
          3. No language communication barriers, or the family members who know the condition can&#xD;
             complete the questionnaire on behalf of the patient, and the data are reliable;&#xD;
&#xD;
          4. Voluntarily agree to participate in this study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Older than 80 or younger than 40&#xD;
&#xD;
          2. Pregnant women&#xD;
&#xD;
          3. Complicating with other lung diseases, such as asthma, pneumonia, bronchiectasis, lung&#xD;
             abscess, interstitial lung disease, confirmed and suspected lung cancer of lung&#xD;
             shadow, active pulmonary tuberculosis, etc&#xD;
&#xD;
          4. Previous lung surgery&#xD;
&#xD;
          5. Cognitive dysfunction&#xD;
&#xD;
          6. Unable to cooperate with lung function test.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Peking University Third Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100080</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>July 1, 2021</study_first_submitted>
  <study_first_submitted_qc>July 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 8, 2021</study_first_posted>
  <last_update_submitted>July 1, 2021</last_update_submitted>
  <last_update_submitted_qc>July 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pulmonary disease; chronic obstructive; Phenotype</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

